{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:43Z","timestamp":1772165683199,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2020,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Although\n 18<\/jats:sup>\n F- FDG PET\/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between\n 18<\/jats:sup>\n F- FDG PET\/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n All patients (\n n<\/jats:italic>\n \u00a0=\u200986) with esophageal adenocarcinoma or squamous cell cancer operated between 2005 and 2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor\u2019s maximal Standardized Uptake Value (SUV\n max<\/jats:sub>\n ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3\/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n High baseline SUV\n max<\/jats:sub>\n was associated with cT3\/4 status and middle-third tumor location, TLG with a cT3\/4 and cN+ status, whereas MTV only with active smoking. A cT3\/4 status was significantly predicted by a SUV\n max<\/jats:sub>\n \u00a0>\u20098.25\u2009g\/mL (\n p<\/jats:italic>\n \u00a0<\u20090.001), TLG\u2009>\u200941.7 (\n p<\/jats:italic>\n \u00a0<\u20090.001) and MTV\u2009>\u200910.70\u2009cm\n 3<\/jats:sup>\n (\n p<\/jats:italic>\n \u00a0<\u20090.01) whereas a SUV\n max<\/jats:sub>\n \u00a0>\u200912.7\u2009g\/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56\u2009months,\n p<\/jats:italic>\n \u00a0=\u20090.030), particularly in squamous cell cancer.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Baseline\n 18<\/jats:sup>\n F- FDG PET\/CT has a high predictive value of preoperative cT stage, as its parameters SUV\n max<\/jats:sub>\n , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV\n max<\/jats:sub>\n \u00a0>\u200912.7\u2009g\/mL may herald early tumor recurrence and poor disease-free survival.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12880-019-0401-x","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T05:35:34Z","timestamp":1580794534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["18F- FDG PET\/CT-derived parameters predict clinical stage and prognosis of esophageal cancer"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1315-1898","authenticated-orcid":false,"given":"Styliani","family":"Mantziari","sequence":"first","affiliation":[]},{"given":"Anastasia","family":"Pomoni","sequence":"additional","affiliation":[]},{"given":"John O.","family":"Prior","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Winiker","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Allemann","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Demartines","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Sch\u00e4fer","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"issue":"9864","key":"401_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2016","unstructured":"Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2016;381(9864):400\u201312.","journal-title":"Lancet"},{"issue":"suppl 5","key":"401_CR2","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50\u20137.","journal-title":"Ann Oncol"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1245\/s10434-011-1738-8","volume":"23","author":"LMA Schreurs","year":"2016","unstructured":"Schreurs LMA, Janssens ACJW, Groen H, et al. Value of EUS in determining curative resectability in reference to CT and FDG-PET: the optimal sequence in preoperative staging of esophageal cancer? Ann Surg Oncol. 2016;23:1021\u20138.","journal-title":"Ann Surg Oncol"},{"key":"401_CR4","doi-asserted-by":"publisher","unstructured":"Kroese TE, Goense L, van Hillegersberg R, et al. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(\/CT): a systematic review and meta-analysis. Dis Esophagus. 2018;31(12). https:\/\/doi.org\/10.1093\/dote\/doy055.","DOI":"10.1093\/dote\/doy055"},{"issue":"9","key":"401_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797\u2013805.","journal-title":"Lancet Oncol"},{"issue":"3","key":"401_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000001905","volume":"265","author":"S Pasquali","year":"2017","unstructured":"Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg. 2017;265(3):481\u201391.","journal-title":"Ann Surg"},{"issue":"3","key":"401_CR7","first-page":"1","volume":"30","author":"V Malik","year":"2017","unstructured":"Malik V, Johnston C, O\u2019Toole D, et al. Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer. Dis Esophagus. 2017;30(3):1\u20138.","journal-title":"Dis Esophagus"},{"issue":"12","key":"401_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/RLU.0000000000002291","volume":"43","author":"S Han","year":"2018","unstructured":"Han S, Kim YJ, Woo S, et al. Prognostic value of volumetric parameters of pretreatment 18F-FDG PET\/CT in esophageal cancer: a systematic review and meta-analysis. Clin Nucl Med. 2018;43(12):887\u201394.","journal-title":"Clin Nucl Med"},{"key":"401_CR9","doi-asserted-by":"crossref","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. Oesophagus including oesophagogastric junction malignant tumors. In: TNM UICC classification of malignant tumours. 7th ed: Wiley-Blackwell Editions; 2011. p. 66\u201372.","DOI":"10.1002\/9780471420194.tnmc10.pub2"},{"issue":"523","key":"401_CR10","first-page":"1165","volume":"12","author":"P Allemann","year":"2016","unstructured":"Allemann P, Mantziari S, Wagner D, et al. Curative treatment for esophageal cancer. Results of a multidisciplinary consensus; traitement curatif du cancer de l\u2019oesophage: consensus multidisciplinaire multicentrique. Rev Med Suisse. 2016;12(523):1165\u20139.","journal-title":"Rev Med Suisse"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mednuc.2017.06.004","volume":"41","author":"S Gnesin","year":"2017","unstructured":"Gnesin S, Deshayes E, Camus F, et al. Quantification and monitoring of PET\/CT data in multicentre trials: the Swiss SAKK 56\/07 trial experience. M\u00e9decine Nucl\u00e9aire. 2017;41:259\u201366.","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"issue":"3","key":"401_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MNM.0000000000000641","volume":"38","author":"W Xu","year":"2017","unstructured":"Xu W, Yu S, Ma Y, et al. No Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET\/CT of cervical primary squamous cell carcinoma. Nucl Med Commun. 2017;38(3):259\u201365.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"401_CR13","first-page":"239","volume":"14","author":"A Imperiale","year":"2011","unstructured":"Imperiale A, Cimarelli S, Brigand C, et al. Does the association of 18F-FDG uptake intensity and lesion topography reveal histological phenotype and tumor differentiation in esophageal cancer? Hell J Nucl Med. 2011;14(3):239\u201342.","journal-title":"Hell J Nucl Med"},{"issue":"3","key":"401_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bjc.6604200","volume":"98","author":"EP van Vliet","year":"2008","unstructured":"van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547\u201357.","journal-title":"Br J Cancer"},{"issue":"1","key":"401_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11307-010-0306-0","volume":"13","author":"A Walker","year":"2011","unstructured":"Walker A, Spier B, Perlman S, et al. Integrated PET\/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol. 2011;13(1):166\u201371.","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"401_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1097\/RLU.0b013e31827083ba","volume":"37","author":"V Malik","year":"2012","unstructured":"Malik V, Johnston C, Donohoe C, et al. (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management. Clin Nucl Med. 2012;37(12):1152\u20138.","journal-title":"Clin Nucl Med"},{"issue":"14","key":"401_CR17","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/cncr.24399","volume":"115","author":"H Kato","year":"2009","unstructured":"Kato H, Nakajima M, Sohda M, et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115(14):3196\u2013203.","journal-title":"Cancer"},{"issue":"1","key":"401_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox113","volume":"31","author":"M Winiker","year":"2018","unstructured":"Winiker M, Mantziari S, Figueiredo SG, et al. Accuracy of preoperative staging for a priori resectable esophageal cancer. Dis Esophagus. 2018;31(1):1\u20136.","journal-title":"Dis Esophagus"},{"issue":"6","key":"401_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1055\/s-2008-1077302","volume":"40","author":"JMT Omloo","year":"2008","unstructured":"Omloo JMT, Sloof GW, Boellaard R, et al. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy. 2008;40(6):464\u201371.","journal-title":"Endoscopy"},{"issue":"2","key":"401_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.athoracsur.2006.03.045","volume":"82","author":"RJ Cerfolio","year":"2006","unstructured":"Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 2006;82(2):391\u20135.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"401_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.athoracsur.2005.09.063","volume":"81","author":"N Rizk","year":"2006","unstructured":"Rizk N, Downey RJ, Akhurst T, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006;81(3):1076\u201381.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"401_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00259-011-1755-7","volume":"38","author":"M Hatt","year":"2011","unstructured":"Hatt M, Visvikis D, Albarghach NM, et al. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191\u2013202.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"401_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00259-019-04307-6","volume":"46","author":"F Hofheinz","year":"2019","unstructured":"Hofheinz F, Li Y, Steffen IG, et al. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(7):1485\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"401_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2967\/jnumed.117.207670","volume":"60","author":"Rebecca B\u00fctof","year":"2018","unstructured":"B\u00fctof R, Hofheinz F, Z\u00f6phel K, et al. Prognostic value of standardized uptake ratio in patients with trimodality treatment of locally advanced esophageal carcinoma. J Nucl Med. 2019;60:192\u20138.","journal-title":"Journal of Nuclear Medicine"},{"issue":"7","key":"401_CR25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00268-017-4422-8","volume":"42","author":"S Mantziari","year":"2018","unstructured":"Mantziari S, Allemann P, Winiker M, Demartines N, Sch\u00e4fer M. Locoregional tumor extension and preoperative smoking are significant risk factors for early recurrence after esophagectomy for cancer. World J Surg. 2018;42(7):2209\u201317.","journal-title":"World J Surg"},{"issue":"2","key":"401_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.gtc.2015.02.015","volume":"44","author":"AM Kaz","year":"2015","unstructured":"Kaz AM, Grady WM, Stachler MD, Bass AJ. Genetic and epigenetic alterations in Barrett\u2019s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 2015;44(2):473\u201389.","journal-title":"Gastroenterol Clin North Am"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-019-0401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12880-019-0401-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-019-0401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T19:13:14Z","timestamp":1611169994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-019-0401-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s12880-019-0401-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18946\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18946\/v2","asserted-by":"object"}]},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Lausanne University Institutional Review Board. On the basis of the general research contentment form, the need for individual consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}